News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Mark Melton

Advertisement

Articles by Mark Melton

Mark Melton

Modular Approaches are Opening the Portal to Better HCP Engagement

ByMark Melton
January 30th 2024

Portals are finally a viable channel as life sciences companies shift to modular to build their digital ecosystems, create and approve content, and deliver omnichannel experiences.

Advertisement

Latest Updated Articles

  • Mark Melton
    Modular Approaches are Opening the Portal to Better HCP Engagement

    Published: January 30th 2024 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

MFN Executive Order Webinar: Inside Trump’s Drug Price Plan

2

Cencora Reveals $1 Billion Investment Plan Enhancing US-Based Distribution Network

3

Pharmaceutical Executive Daily: Pfizer Files Lawsuits Against Metsera and Novo Nordisk

4

FDA Approves Kygevvi Becoming the First Treatment for Thymidine Kinase 2 Deficiency

5

Roundup: Pharma Industry Forms Strategic Collaborations Bolstering Research and Development Pipelines for Autoimmune and Oncology Therapies

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us